OMass Therapeutics, a UK BioTech company developing small molecule therapeutics against highly validated target ecosystems, announced an oversubscribed €275 million (£230 million) Series C round. The round was co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with additional participation from Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences.…
One of Australia’s hardest-working comedians is still laughing at the timing of a breast cancer diagnosis just as she set out to launch a book about wellness.
Many survey methods assume people weigh every feature of a candidate or policy. New research suggests most don’t: mental shortcuts dominated, and the strategy people used often shifted from one issue…
Eli Lilly is interested in R&D efforts to “improve the profile of ibogaine,” the pharma giant’s neuroscience president said at a psychedelics conference Thursday.
